28 min listen
Designing Small-Molecule, Immuno-Oncology Drugs That Act Like Biologics
FromThe Bio Report
ratings:
Length:
23 minutes
Released:
Feb 13, 2019
Format:
Podcast episode
Description
Kleo Pharmaceuticals is a developing next-generation immuno-oncology drugs that are small-molecule compounds designed to act like biologics. Kleo’s compounds activate patients’ immune systems to target and destroy cancer cells but are faster and less costly to design and produce than biologics. We spoke to Doug Manion, CEO of Kleo, about the company’s platform technology, why he thinks it will produce safer and more effective immunotherapies, and the potential to use these compounds in conjunction with existing biologics to enhance their activity.
Released:
Feb 13, 2019
Format:
Podcast episode
Titles in the series (100)
How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report